Infosys Ltd, India’s second-largest IT services firm, has secured a landmark £1.2 billion ($1.59 billion) contract from the UK’s National Health Service Business Services Authority (NHSBSA) to modernize its workforce management and payroll system.
The 15-year agreement represents one of Infosys’ biggest wins in the public sector, coming at a time when the $283-billion Indian IT industry faces global economic headwinds, trade uncertainties, and evolving immigration norms in key markets like the United States.
Under the contract, Infosys will design and implement a new, data-driven workforce management platform to replace the NHS’s existing Electronic Staff Record (ESR) system. The platform will handle payroll and HR functions for 1.9 million NHS employees across England and Wales, managing transactions worth over £55 billion annually.
According to Infosys, the platform will integrate artificial intelligence (AI) and analytics through its proprietary Infosys Topaz technology suite, aiming to enhance workforce planning, streamline operations, and improve user experience. It will also support the NHS’s long-term digital transformation and its 10-year health workforce strategy.
Michael Brodie, Chief Executive of NHSBSA, said the partnership goes “far beyond simply replacing ESR — it will be a strategic enabler for building a workforce that is fit for the future.”
Salil Parekh, CEO and Managing Director of Infosys, highlighted that the company’s global experience in digital transformation and AI-led solutions will help deliver “a platform that drives efficiency today and empowers the NHS into the future.”
Infosys is scheduled to announce its Q2 FY26 financial results on October 16, where investors will be watching closely for updates on large deal momentum amid a sluggish global demand environment.
Disclaimer:
This article is intended solely for educational and informational purposes. The securities or companies mentioned are provided as examples and should not be considered as recommendations. Nothing contained herein constitutes personal financial advice or investment recommendations. Readers are advised to conduct their own research and consult a qualified financial advisor before making any investment decisions.
Investments in securities markets are subject to market risks. Please read all related documents carefully before investing.